Insight on Pharmaceuticals and Healthcare in United Kingdom

Published within

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

Type Product title / description Pub Price
Report
Report

R&D Trends: Prostate Cancer - Newly approved therapies shift treatment dynamics for castrate-resistant disease

Review of key R&D trends in prostate cancer including; dynamics of the pipeline, comparator therapies, target product profile, trends in clinical trial design, innovative early-stage projects, and the future of prostate cancer treatment.

Published By Datamonitor
17 Jun 2011 $2800
Buy
Report
Report

R&D Trends: Attention-Deficit Hyperactivity Disorder - Growing pipeline indicates a trend towards adjunctive and adult therapy

This report reviews the key trends in the development of new ADHD drugs across the seven major markets. Also includes analyses of clinical trial design, target product profile, innovative early-stage projects, and future treatment developments.

Published By Datamonitor
21 Jun 2011 $2800
Buy
Report
Report

Hot Topics in Type 2 Diabetes: Physician Perceptions of Insulin - Physician survey provides insights into insulin usage and needs

Datamonitor presents physician primary research on insulin in the type 2 diabetes treatment algorithm, including patient share by class, brand splits, trends and unmet needs. Focused on the US, Japan, France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
21 Jun 2011 $2800
Buy
Report
Report

Product Profiles: Allergic Rhinitis - Heavily genericized market sees areas of innovation

Allergic rhinitis is an established, yet dynamic market. The April 2011 FDA filing of Dymista (azelastine/fluticasone; Meda/Cipla) could bring a new class to the market, while efforts to retain brand share have been seen in monotherapy classes.

Published By Datamonitor
23 Jun 2011 $6400
Buy
Report
Report

Product Profiles: Systemic Lupus Erythematosus – Benlysta approval brings lessons and hope to market

Datamonitor’s survey of 108 US rheumatologists after the momentous approval of Benlysta (belimumab; Human Genome Sciences/GlaxoSmithKline) assesses its impact on the market. Additional pipeline products have moved into Phase III during the last year.

Published By Datamonitor
27 Jun 2011 $6400
Buy
Report
Report

R&D Trends: Rheumatoid Arthritis – Approaching an era of novel kinase inhibitors

Review of candidates in development for rheumatoid arthritis across the seven major markets, highlighting key trends, as well as analyses of clinical trial design, innovative early-stage projects and hypothesizing on how future treatment may evolve.

Published By Datamonitor
01 Jul 2011 $2800
Buy
Report
Report

Epidemiology: Acute Coronary Syndrome - Now affecting primarily the oldest populations

Overview of acute coronary syndrome definition and review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year forecast, and assessment of key patient segments across the seven major markets.

Published By Datamonitor
04 Jul 2011 $2800
Buy
Report
Report

R&D Trends: Skin and soft tissue infections - MRSA threat drives R&D interest in an increasingly fragmented market

The emergence of methicillin-resistant Staphylococcus aureus (MRSA) has driven R&D interest in skin and soft tissue infections (SSTIs). This module reviews pipeline trends, clinical trial design, and future treatment paradigms for SSTIs.

Published By Datamonitor
05 Jul 2011 $2800
Buy
Report
Report

Epidemiology: Bipolar Disorders – Population growth to mean more patients with bipolar disorders

Overview of bipolar disorders, definition, and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year prevalent case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
06 Jul 2011 $2800
Buy
Report
Report

Epidemiology: HIV – Antiretrovirals prevail as patient population grows

This report provides in-depth analysis of HIV patient populations, a 10-year diagnosed prevalence case forecast, and key patient segments across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).

Published By Datamonitor
08 Jul 2011 $2800
Buy

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

No help is available.